MedTrace Logo

Response of Patients on Surveillance for Prostate Cancer to Dutasteride

NCT01525914 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 100

Last updated 2012-02-03

No results posted yet for this study

Summary

Hypothesis: That, in men on surveillance for favorable risk prostate cancer treated with dutasteride, prostate specific antigen (PSA) kinetics is of value in identifying those men who harbor occult high grade prostate cancer.

The study will determine the prevalence of a secondary rise in PSA \> 0.5 ng/ml and the PSA doubling time in subjects on surveillance being treated with dutasteride.

Conditions

Interventions

DRUG

Dutasteride

dutasteride 0.5mg daily

Sponsors & Collaborators

  • Toronto Sunnybrook Regional Cancer Centre

    collaborator OTHER

  • Sunnybrook Health Sciences Centre

    lead OTHER

Principal Investigators

  • Laurence Klotz, MD · Sunnybrook Health Sciences Centre

Eligibility

Min Age
18 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-05-31
Primary Completion
2010-08-31
Completion
2010-08-31

Countries

  • Canada

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01525914 on ClinicalTrials.gov